NovoCure Insider Sells $14,641 in Stock

Michal Nath Puri, a NovoCure insider, sold 1,100 shares of the company's stock.

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

NovoCure Limited (NASDAQ:NVCR) insider Michal Nath Puri sold 1,100 shares of the company's stock on March 4th. The shares were sold at an average price of $13.31, for a total transaction value of $14,641. Following the sale, Puri still owns 201,322 shares in the company, valued at approximately $2,679,595.82.

Why it matters

Insider transactions, such as this sale by Puri, can provide insights into a company's performance and management's views on the stock's valuation. While a single insider sale does not necessarily indicate any broader concerns, it is still noteworthy for investors to track insider activity around a stock.

The details

Puri's sale represents a 0.54% decrease in his ownership stake in NovoCure. The company is a medical equipment provider focused on developing Tumor Treating Fields, a novel anti-mitotic therapy for solid tumors. NovoCure's stock has traded in a range of $9.82 to $21.55 over the past 12 months.

  • The transaction occurred on Wednesday, March 4th, 2026.

The players

Michal Nath Puri

An insider at NovoCure Limited who sold 1,100 shares of the company's stock.

NovoCure Limited

A medical equipment provider that develops Tumor Treating Fields, a novel anti-mitotic therapy for solid tumors.

Got photos? Submit your photos here. ›

The takeaway

This insider sale by Puri, while relatively small in size, is still noteworthy for investors to monitor as it could signal management's views on the company's valuation or performance. However, a single insider transaction does not necessarily indicate any broader concerns, and investors should consider this information in the context of NovoCure's overall business and financial performance.